Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?

International Journal of Impotence Research volume 23, pages 17–23 (2011)Cite this article

Subjects

Abstract

Premature ejaculation (PE) is considered to be the most common male sexual dysfunction. The realization that PE may co-exist with ED prompted the use of PDE5-i's alone or in combination with selective serotonin reuptake inhibitors (SSRIs) for treating ejaculatory disorders. Until recently, there was little evidence that PDE5-i's alone may have a role in the treatment of PE in the absence of ED, and current available treatments include only on-demand dapoxetine. However, available data indicate that there is clinical, anatomical, physiological, pharmacological and genetic evidence to explain the efficacy of PDE5-i's. Nine manuscripts that examined the efficacy of PDE5-i's in the treatment of PE, alone or in combination with SSRIs, were retrieved. All studies reported some significant changes in the intravaginal ejaculatory latency time and sexual satisfaction scores, although not all were clinically meaningful. Well-designed multicenter studies are urgently required to further elucidate the efficacy and safety, as well as the mechanisms of action of PDE5-i's in the treatment of PE. The aim of this review is to discuss basic rationale and to show clinical evidence sustaining the possibility to use off-label PDE5-i's to treat PE.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J . The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007; 51: 816–824.

    Article  Google Scholar 

  2. Jannini EA, Lombardo F, Lenzi A . Correlation between ejaculatory and erectile dysfunction. Int J Androl 2005; 28 (Suppl 2): 40–45.

    Article  Google Scholar 

  3. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17: 39–57.

    Article  CAS  Google Scholar 

  4. Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M . A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2005; 2: 492–497.

    Article  Google Scholar 

  5. McMahon CG, Abdo C, Incrocci L, Perelman M, Rowland D, Waldinger M et al. Disorders of orgasm and ejaculation in men. J Sex Med 2004; 1: 58–65.

    Article  Google Scholar 

  6. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF et al. Premature ejaculation: an observational study of men and their partners. J Sex Med 2005; 2: 358–367.

    Article  Google Scholar 

  7. McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I et al. International Society for Sexual Medicine Ad Hoc Committee for Definition of Premature Ejaculation. An evidence-based definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int 2008; 102: 338–350.

    Article  Google Scholar 

  8. Althof S, Rowland D . Identifying constructs and criteria for the diagnosis of premature ejaculation: implication for making errors of classification. BJU Int 2008; 102: 708–712.

    Article  Google Scholar 

  9. Abdel-Hamid IA . Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs 2004; 64: 13–26.

    Article  CAS  Google Scholar 

  10. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 1998; 216: 139–147.

    Article  CAS  Google Scholar 

  11. Schultheiss D, Müller SV, Nager W, Stief CG, Schlote N, Jonas U et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol 2001; 19: 46–50.

    Article  CAS  Google Scholar 

  12. Sato Y, Horita H, Kurohata T, Adachi H, Tsukamoto T . Effect of the nitric oxide level in the medial preoptic area on male copulatory behavior in rats. Am J Physiol 1998; 274: R243–R247.

    CAS  PubMed  Google Scholar 

  13. Castellano M, Rizzoni D, Beschi M, Muiesan ML, Porteri E, Bettoni G et al. Relationship between sympathetic nervous system activity, baroreflex and cardiovascular effects after acute nitric oxide synthesis inhibition in humans. J Hypertens 1995; 13: 1153–1161.

    Article  CAS  Google Scholar 

  14. Krukoff TL . Central regulation of autonomic function: no brakes? Clin Exp Pharmacol Physiol 1998; 25: 474–478.

    Article  CAS  Google Scholar 

  15. Pfaus JG . Neurobiology of sexual behavior. Curr Opin Neurobiol 1999; 9: 751–758.

    Article  CAS  Google Scholar 

  16. Hull EM, Lumley LA, Matuszewich L, Dominguez J, Moses J, Lorrain DS . The roles of nitric oxide in sexual function of male rats. Neuropharmacology 1994; 33: 1499–1504.

    Article  CAS  Google Scholar 

  17. Kim TS, Ko IG, Sung YH, Kim SE, Kim BK, Park SK et al. Vardenafil increases cell proliferation in the dentate gyrus through enhancement of serotonin expression in the rat dorsal raphe. J Korean Med Sci 2009; 24: 1099–1104.

    Article  CAS  Google Scholar 

  18. Heuer O, Uckert S, Machtens SA, Stief CG, Tsikas D, Frölich JC et al. Effects of various nitric oxide donating agents on the contractility and cyclic nucleotide turnover of human seminal vesicles in vitro. Urology 2002; 59: 958–962.

    Article  Google Scholar 

  19. Dixon JS, Jen PY . Development of nerves containing nitric oxide synthase in the human male urogenital organs. Br J Urol 1995; 76: 719–725.

    Article  CAS  Google Scholar 

  20. Uckert S, Bazrafshan S, Scheller F, Mayer ME, Jonas U, Stief CG . Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors. Urology 2007; 70: 185–189.

    Article  Google Scholar 

  21. Jen PY, Dixon JS, Gosling JA . Co-localization of nitric oxide synthase, neuropeptides and tyrosine hydroxylase in nerves supplying the human post-natal vas deferens and seminal vesicle. Br J Urol 1997; 80: 291–299.

    Article  CAS  Google Scholar 

  22. Grozdanovic Z, Goessl C . Comparative localization of heme oxygenase-2 and nitric oxide synthase in the autonomic innervation to the human ductus deferens and seminal vesicle. J Urol 1999; 162: 2156–2161.

    Article  CAS  Google Scholar 

  23. Uckert S, Bazrafshan S, Sonnenberg JE, Kuczyk MA . Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation. J Sex Med 2009; 6: 408–414.

    Article  Google Scholar 

  24. Machtens S, Ckert S, Stief CG, Tsikas D, Frlich JC, Jonas U . Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro. Urology 2003; 61: 479–483.

    Article  Google Scholar 

  25. Bultmann R, Klebroff W, Starke K . Nucleotide-evoked relaxation of rat vas deferens: possible mechanisms. Eur J Pharmacol 2002; 436: 135–143.

    Article  CAS  Google Scholar 

  26. Bialy M, Beck J, Abramczyk P, Trzebski A, Przybylski J . Sexual behavior in male rats after nitric oxide synthesis inhibition. Physiol Behav 1996; 60: 139–143.

    Article  CAS  Google Scholar 

  27. Moriyama N, Nasu K, Takeuchi T, Akiyama K, Murata S, Nishimatsu H et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br J Pharmacol 1997; 122: 1009–1014.

    Article  CAS  Google Scholar 

  28. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T . Ejaculatory disorder caused by α-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 2006; 13: 1311–1316.

    Article  CAS  Google Scholar 

  29. Vignozzi L, Filippi S, Morelli A, Luconi M, Jannini E, Forti G et al. Regulation of epididymal contractility during semen emission, the first part of the ejaculatory process: a role for estrogen. J Sex Med 2008; 5: 2010–2016.

    Article  Google Scholar 

  30. Aversa A, Caprio M, Antelmi A, Brama M, Greco E, Fabbri A et al. Acute tadalafil exposure stimulates aromatase expression in human adipocytes in vitro. J Sex Med 2009; 6 (Suppl 5): 403.

    Google Scholar 

  31. Medina P, Segarra G, Torondel B, Chuan P, Domenech C, Vila JM et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafil. Br J Pharmacol 2000; 131: 871–874.

    Article  CAS  Google Scholar 

  32. Kriegsfeld LJ, Demas GE, Huang PL, Burnett AL, Nelson RJ . Ejaculatory abnormalities in mice lacking the gene for endothelial nitric oxide synthase (eNOS−/−). Physiol Behav 1999; 67: 561–566.

    Article  CAS  Google Scholar 

  33. Jain NK, Patil CS, Singh A, Kulkarni SK . Sildenafil-induced peripheral analgesia and activation of the nitric oxidecyclic GMP pathway. Brain Res 2001; 909: 170–178.

    Article  CAS  Google Scholar 

  34. Wang WF, Minhas S, Ralph DJ . Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation. Int J Androl 2006; 29: 503–509.

    Article  CAS  Google Scholar 

  35. Rosenberg MT, Adams PL, McBride TA, Roberts JN, McCallum SW . Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int J Clin Pract 2009; 63: 27–34.

    Article  CAS  Google Scholar 

  36. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H . The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol 2007; 52: 1331–1339.

    Article  Google Scholar 

  37. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.

    Article  CAS  Google Scholar 

  38. McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker N, Haughie S et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005; 2: 368–375.

    Article  CAS  Google Scholar 

  39. Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 2009; 21: 221–227.

    Article  CAS  Google Scholar 

  40. Aversa A, Mazzilli F, Rossi T, Delfino M, Isidori AM, Fabbri A . Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod 2000; 15: 131–134.

    Article  CAS  Google Scholar 

  41. Mondaini N, Ponchietti R, Muir GH, Montorsi F, Di Loro F, Lombardi G et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. Int J Impot Res 2003; 15: 225–228.

    Article  CAS  Google Scholar 

  42. Gökçe A, Demirtas A, Halis F, Ekmekcioglu O . In vitro measurement of ejaculation latency time (ELT) and the effects of vardenafil on ELT on lifelong premature ejaculators: placebo-controlled, double-blind, cross-over laboratory setting. Int Urol Nephrol 2010; 42: 881–887.

    Article  Google Scholar 

  43. Mathers MJ, Klotz T, Roth S, Lummen G, Sommer F . Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. Andrologia 2009; 41: 169–175.

    Article  CAS  Google Scholar 

  44. Wang WF, Wang Y, Minhas S, Ralph DJ . Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol 2007; 14: 331–335.

    Article  CAS  Google Scholar 

  45. Abdel-Ahmid IA, El-Naggar EA, El-Gilany AH . Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impotence Res 2001; 13: 41–45.

    Article  Google Scholar 

  46. Mattos RM, Marmo Lucon A, Srougi M . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008; 80: 162–165.

    Article  CAS  Google Scholar 

  47. Chen J, Mabjeesh NJ, Matzkin H, Greenstein A . Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 2003; 61: 197–200.

    Article  Google Scholar 

  48. Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002; 168: 2486–2489.

    Article  CAS  Google Scholar 

  49. Hosseini MM, Yarmohammadi H . Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int 2007; 79: 28–32.

    Article  CAS  Google Scholar 

  50. Porst H, McMahon CG, Althof SE, Sharlip I, Bull S, Aquilina JW et al. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. J Sex Med 2010; 7: 2231–2242.

    Article  Google Scholar 

  51. Linton KD, Wylie KR . Recent advances in the treatment of premature ejaculation. Drug Des Devel Ther 2010; 4: 1–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Safarinejad MR, Hosseini SY . Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2006; 26: 27–31.

    Article  CAS  Google Scholar 

  53. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA . Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med 2008; 5: 188–193.

    Article  CAS  Google Scholar 

  54. Eradiri O, Sista S, Lai JC-K, Danyluk A, Brett V . Bioavailability of extended release and immediate-release formulations of tramadol HCl. J Clin Pharmacol 2006; 46: 1091–1096.

    Google Scholar 

  55. Aversa A, Caprio M, Antelmi A, Armani A, Greco EA, Brama M et al. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J Sex Med 2011 (e-pub ahead of print); doi:10.1111/j.1743-6109.2010.02152.x.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Pathophysiology, Sapienza University of Rome, Rome, Italy

    A Aversa, D Francomano, R Bruzziches, M Natali, G Spera & A Lenzi

Authors
  1. A Aversa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Francomano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Bruzziches
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Natali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Spera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Lenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Aversa.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aversa, A., Francomano, D., Bruzziches, R. et al. Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?. Int J Impot Res 23, 17–23 (2011). https://doi.org/10.1038/ijir.2010.34

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2010.34

Keywords

This article is cited by

Search

Advanced search

Quick links